Compare AES Corp (AES) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AES Corp vs TransMedics Group Inc — how do they compare? AES Corp trades at $14.65 (market cap $10.43B), while TransMedics Group Inc trades at $70.14 (market cap $2.46B). The key difference: AES Corp is far larger — about 4.2× TransMedics Group Inc's market cap, and AES Corp pays a 4.81% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| AES | TMDX | |
|---|---|---|
Market Cap | $10.43B | $2.46B |
Sector | Utilities | Technology |
52-Week High | $17.28 | $150.42 |
52-Week Low | $11.07 | $61.99 |
Enterprise Value | $39.77B | $2.86B |
Dividend Yield | 4.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AES trades at $14.62, up 0.27% on the day, with strong fundamentals including a P/E of 7.59 and net income margin of 10.82%. Recent quarters show consistent earnings beats, while technical indicators signal bearish momentum. The company's pending $33.4 billion acquisition by a BlackRock/EQT consortium, approved by stockholders on June 26, 2026, caps near-term upside at $15 per share but provides a stable exit pathway.
The investment case hinges on the acquisition closing, offering a 2.6% gain to the $15 buyout price plus dividend yield. Risks include deal completion uncertainty and shareholder litigation. With no sell-side analysts recommending sell, the stock presents a low-risk arbitrage opportunity with defined upside and limited downside if the transaction proceeds as planned.
TMDX trades at $71.23, up 3.44% on the day, but technical indicators signal a bearish trend. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE for 2025, though Q1 2026 earnings missed expectations. Recent strategic investments in European organ logistics aim to expand its competitive moat, but margin pressure from expansion costs is a key concern noted by analysts (Zacks Investment Research, 2026-07-07).
The investment outlook is mixed: strong analyst consensus (75% buy ratings) and a $108.71 price target suggest significant upside, but near-term execution risks and bearish technicals warrant caution. Long-term growth drivers in transplant logistics are compelling, yet investors must weigh expansion costs against the potential for market share gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
